NVS Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 18.03% compared to Novartis AG's net margin of 15.02%. Novartis AG's return on equity of 32.47% beat AstraZeneca PLC's return on equity of 23.12%.

Novartis AG has a consensus price target of $139.80, signalling downside risk potential of -14.71%. On the other hand AstraZeneca PLC has an analysts' consensus of $135.50 which suggests that it could fall by -58.3%. Given that AstraZeneca PLC has more downside risk than Novartis AG, analysts believe Novartis AG is more attractive than AstraZeneca PLC.

Novartis AG has a beta of 0.508, which suggesting that the stock is 49.176% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.381%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.44%. AstraZeneca PLC offers a yield of 1.5% to investors and pays a quarterly dividend of $2.15 per share. Novartis AG pays 42.8% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.3B, which are smaller than AstraZeneca PLC quarterly revenues of $15.5B. Novartis AG's net income of $2.4B is higher than AstraZeneca PLC's net income of $2.3B. Notably, Novartis AG's price-to-earnings ratio is 22.81x while AstraZeneca PLC's PE ratio is 63.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.85x versus 11.08x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of 18.03% compared to Novartis AG's net margin of 27.55%. Novartis AG's return on equity of 32.47% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Novartis AG has a consensus price target of $139.80, signalling downside risk potential of -14.71%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $155.42 which suggests that it could grow by 2.85%. Given that Gilead Sciences, Inc. has higher upside potential than Novartis AG, analysts believe Gilead Sciences, Inc. is more attractive than Novartis AG.

Novartis AG has a beta of 0.508, which suggesting that the stock is 49.176% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.44%. Gilead Sciences, Inc. offers a yield of 2.09% to investors and pays a quarterly dividend of $0.79 per share. Novartis AG pays 42.8% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.3B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.9B. Novartis AG's net income of $2.4B is higher than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Novartis AG's price-to-earnings ratio is 22.81x while Gilead Sciences, Inc.'s PE ratio is 22.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.85x versus 6.45x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 18.03% compared to Novartis AG's net margin of 21.74%. Novartis AG's return on equity of 32.47% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Novartis AG has a consensus price target of $139.80, signalling downside risk potential of -14.71%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 10.95%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Novartis AG, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Novartis AG.

Novartis AG has a beta of 0.508, which suggesting that the stock is 49.176% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.44%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.94 per share. Novartis AG pays 42.8% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.3B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Novartis AG's net income of $2.4B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Novartis AG's price-to-earnings ratio is 22.81x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.85x versus 5.93x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.47% beat Roche Holding AG's return on equity of 28.65%.

Novartis AG has a consensus price target of $139.80, signalling downside risk potential of -14.71%. On the other hand Roche Holding AG has an analysts' consensus of $58.80 which suggests that it could fall by -0.64%. Given that Novartis AG has more downside risk than Roche Holding AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.508, which suggesting that the stock is 49.176% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.440, suggesting its less volatile than the S&P 500 by 56.044%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.44%. Roche Holding AG offers a yield of 2.35% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 42.8% of its earnings as a dividend. Roche Holding AG pays out 58.07% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.3B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $2.4B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 22.81x while Roche Holding AG's PE ratio is 24.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.85x versus 5.13x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.